Clinical experience with preoperative chemotherapy for osteosarcoma

Area of Science:

• Oncology
• Orthopedic Surgery
• Chemotherapy

Background:

• Osteosarcoma is a primary bone cancer often treated with chemotherapy.
• Neoadjuvant chemotherapy is a standard treatment approach for osteosarcoma.
• Assessing treatment response is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the tolerability and surgical impact of preoperative chemotherapy in osteosarcoma patients.
• To determine the prognostic significance of tumor necrosis following neoadjuvant chemotherapy for osteosarcoma.
• To correlate the extent of tumor necrosis with patient survival outcomes.

Main Methods:

• Retrospective analysis of 15 consecutive osteosarcoma patients treated with preoperative chemotherapy since 1978.
• Assessment of chemotherapy tolerability and surgical procedure impact.
• Evaluation of post-chemotherapy tumor necrosis extent and correlation with survival data.

Main Results:

• Preoperative chemotherapy was well-tolerated and did not compromise surgical procedures.
• The extent of tumor necrosis after chemotherapy was found to be biologically significant.
• Patients exhibiting extensive necrosis demonstrated superior relapse-free survival and overall survival compared to those with minimal necrosis.

Conclusions:

• Preoperative chemotherapy is a viable treatment option for osteosarcoma, showing good tolerability.
• Tumor necrosis following neoadjuvant chemotherapy serves as a critical prognostic indicator in osteosarcoma.
• Achieving significant tumor necrosis is associated with improved long-term outcomes for osteosarcoma patients.